|
DCF -Bewertung der Dynavax Technologies Corporation (DVAX)
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Dynavax Technologies Corporation (DVAX) Bundle
Entdecken Sie den tatsächlichen Wert der Dynavax Technologies Corporation (DVAX) mit unserem DCF-Taschenrechner von Professional Grade! Passen Sie die wichtigsten Annahmen an, erkunden Sie verschiedene Szenarien und bewerten Sie, wie sich Änderungen auf die Bewertung der Dynavax Technologies Corporation (DVAX) auswirken - alles innerhalb einer bequemen Excel -Vorlage.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.6 | 439.4 | 722.7 | 232.3 | 277.2 | 357.6 | 461.3 | 595.0 | 767.5 | 990.0 |
| Revenue Growth, % | 0 | 844 | 64.45 | -67.86 | 19.36 | 28.99 | 28.99 | 28.99 | 28.99 | 28.99 |
| EBITDA | -46.8 | 95.7 | 307.7 | 9.7 | 45.7 | -10.7 | -13.8 | -17.8 | -23.0 | -29.7 |
| EBITDA, % | -100.63 | 21.78 | 42.58 | 4.16 | 16.48 | -3 | -3 | -3 | -3 | -3 |
| Depreciation | 9.3 | 7.0 | 6.7 | 7.3 | 8.1 | 20.5 | 26.4 | 34.0 | 43.9 | 56.6 |
| Depreciation, % | 20.05 | 1.6 | 0.92267 | 3.13 | 2.9 | 5.72 | 5.72 | 5.72 | 5.72 | 5.72 |
| EBIT | -56.2 | 88.7 | 301.0 | 2.4 | 37.6 | -16.8 | -21.7 | -28.0 | -36.2 | -46.6 |
| EBIT, % | -120.68 | 20.18 | 41.65 | 1.03 | 13.58 | -4.71 | -4.71 | -4.71 | -4.71 | -4.71 |
| Total Cash | 165.0 | 546.0 | 624.4 | 742.3 | 713.8 | 347.9 | 448.7 | 578.8 | 746.6 | 963.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 22.7 | 131.8 | 147.5 | 44.5 | 46.9 | 96.7 | 124.7 | 160.9 | 207.5 | 267.6 |
| Account Receivables, % | 48.68 | 30 | 20.41 | 19.17 | 16.92 | 27.04 | 27.04 | 27.04 | 27.04 | 27.04 |
| Inventories | 63.7 | 61.3 | 59.4 | 53.3 | 70.1 | 121.9 | 157.2 | 202.8 | 261.5 | 337.4 |
| Inventories, % | 136.82 | 13.96 | 8.23 | 22.94 | 25.27 | 34.08 | 34.08 | 34.08 | 34.08 | 34.08 |
| Accounts Payable | 3.3 | 2.6 | 3.2 | 5.2 | 9.1 | 9.8 | 12.6 | 16.3 | 21.0 | 27.1 |
| Accounts Payable, % | 7.11 | 0.59166 | 0.44432 | 2.26 | 3.27 | 2.74 | 2.74 | 2.74 | 2.74 | 2.74 |
| Capital Expenditure | -11.1 | -9.5 | -7.1 | -4.1 | -6.4 | -22.2 | -28.6 | -36.9 | -47.6 | -61.4 |
| Capital Expenditure, % | -23.78 | -2.16 | -0.98785 | -1.77 | -2.29 | -6.2 | -6.2 | -6.2 | -6.2 | -6.2 |
| Tax Rate, % | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 |
| EBITAT | -68.5 | 87.8 | 299.9 | 3.5 | 33.3 | -16.4 | -21.2 | -27.3 | -35.2 | -45.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -153.3 | -22.2 | 286.2 | 117.8 | 19.7 | -119.0 | -83.9 | -108.2 | -139.6 | -180.0 |
| WACC, % | 9.52 | 9.51 | 9.52 | 9.52 | 9.46 | 9.51 | 9.51 | 9.51 | 9.51 | 9.51 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -472.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -184 | |||||||||
| Terminal Value | -2,446 | |||||||||
| Present Terminal Value | -1,554 | |||||||||
| Enterprise Value | -2,026 | |||||||||
| Net Debt | 154 | |||||||||
| Equity Value | -2,180 | |||||||||
| Diluted Shares Outstanding, MM | 133 | |||||||||
| Equity Value Per Share | -16.35 |
What You Will Get
- Real Dynavax Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Dynavax's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Gain access to reliable historical data and future forecasts for Dynavax Technologies Corporation (DVAX).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: Utilize intuitive charts and summaries to clearly visualize your valuation outcomes.
- Suitable for All Experience Levels: Designed with an easy-to-navigate format for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-formatted Excel file containing Dynavax Technologies Corporation’s (DVAX) financial information.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various projections and evaluate results side by side effortlessly.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose This Calculator for Dynavax Technologies Corporation (DVAX)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, investment managers, and industry consultants.
- Accurate Data: Dynavax’s historical and projected financial information is preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them to real-world scenarios.
- Researchers: Utilize advanced models for analyzing vaccine efficacy and safety data.
- Investors: Evaluate your investment strategies and analyze valuation metrics for Dynavax Technologies Corporation (DVAX).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Healthcare Professionals: Understand how biotech companies like Dynavax are assessed in the market.
What the Template Contains
- Pre-Filled DCF Model: Dynavax Technologies Corporation’s (DVAX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to Dynavax.
- Financial Ratios: Evaluate Dynavax’s profitability, leverage, and efficiency metrics.
- Editable Inputs: Adjust assumptions such as growth rates, margins, and CAPEX to tailor your analysis.
- Financial Statements: Comprehensive annual and quarterly reports to facilitate in-depth analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and outcomes for Dynavax.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.